다발성 경화증(MS) : KOL의 견해

This report provides a comprehensive analysis of the current and future landscape of multiple sclerosis (MS) therapies, focusing on the decline of oral disease-modifying therapies (DMTs) and the rise of higher-efficacy treatments. It examines the market dynamics of key therapies like Zeposia, Mavenclad, and Tysabri, and explores the potential of emerging treatments such as masitinib and tolebrutinib.

Key questions answered:

• 1. What events are impacting the uptake of oral DMTs?
• 2. How are therapies perceived by the medical community in terms of efficacy, tolerability, and ease of administration?
• 3. Which recently completed or ongoing clinical trials have the greatest potential to affect prescribing trends?
• 4. What will DMTs need to show to become the treatment of choice in specific therapy lines?
• 5. How will the use of each current and pipeline DMT change in the future in terms of line of therapy and preference?
• 6. What will pipeline products need to show in terms of efficacy and tolerability to compete with current therapies?
• 7. Which pipeline products are the most promising, and how will they impact current market players?
• 8. How will the treatment landscape for MS evolve in the future for each patient segment and line of therapy?

Key brands covered in this report:

Companies:

Table of Contents

Executive summary

Treatment algorithm

Research objectives

• Marketed drugs
  • Oral disease-modifying therapies
  • Second-generation sphingosine modulators
  • Mavenclad (cladribine; Merck Group)
  • Tysabri (natalizumab; Biogen)
  • Anti-CD20 monoclonal antibodies
• Pipeline drugs
  • Masitinib (AB Science)
  • Tolebrutinib (Sanofi)
  • Fenebrutinib (Roche)
  • Remibrutinib (Novartis)
  • Vidofludimus calcium (IMU-838; Immunic)
  • Frexalimab (Sanofi/ImmuNext)
• Earlier-stage approaches for MS
  • Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe